SEC Form 4 · accession 0000899243-17-020279
Global Blood Therapeutics, Inc. · GBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ted W Love
Officer — See Remarks · Director
Period of report
Aug 11, 2017
Accepted (ET)
Aug 14, 2017 · 9:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 11, 2017 | D | 124,106 | $3.395 | D | 1,027,850 | D | |
| Common Stock | holding | — | — | — | 2,500 | I | By daughter | |
| Common Stock | holding | — | — | — | 2,500 | I | By daughter |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF2,F3 | — | Aug 11, 2017 | A | 262,500 | D | — | — | Common Stock | 262,500 | 262,500 | D |
Explanation of responses
- F1Represents unvested shares of Common Stock repurchased by the Issuer at the original purchase price paid by the Reporting Person because the conditions for the vesting of such shares were not achieved within the timeframes specified for such vesting.
- F2Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock.
- F3The RSUs vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
Remarks
Chief Executive Officer and President